An intelligence hub innovating and accelerating groundbreaking therapies to address unmet medicinal needs
Please enter subscribe form shortcode
Please enter instagram feed shortcode
Despite major breakthroughs in cancer therapies, about 10 million people are dying from various cancers yearly and are projected to get worse. Autoimmune diseases are becoming the hidden leading cause of death among females. There are various infections that occasionally break out into epidemics and pandemics, mainly due to drug resistance.
From our diligence so far, the single-target medicine approach is not adequate to stop cancers and immune related diseases. The complex network of immune-related mechanisms requires combination of much larger number of molecules, than we have imagined, that treat all underlying factors simultaneously to avoid adaptive drug resistance and ensure sustained efficacy.
For better treatment outcome for patients, we are using our Intelligence Hub to drive innovation and advance ADJUVANTS that will combine with the SINGLE-TARGET medicines of various modalities (small-molecules, nucleic acids, monoclonal and bispecific antibodies, recombinant proteins, antibody-drug conjugates, vaccines, cell-gene therapies) to enhance and sustain their efficacy.
PARTNERING
